Filtered By:
Drug: Tysabri

This page shows you your search results in order of date.

Order by Relevance | Date

Total 23 results found since Jan 2013.

A Case of Multiple Sclerosis —Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature
Complications involving the central nervous system (CNS) occur in 9–14% of patients following allogeneic hematopoietic stem cell transplantation (HSCT), including stroke-like episodes, demyelination, encephalitis, and nonspecific neurological symptoms. Here we report a case of multiple sclerosis (MS) like relapsing remitting encephalomyelitis following allogeneic HSCT, which did not respond to disease modifying therapies (DMTs) and “domino” autologous HSCT. A 53-year-old male was treated with allogeneic HSCT for lymphoid blast transformation of chronic myeloid leukemia. Ten months later he presented with confusion, s...
Source: Frontiers in Immunology - May 4, 2020 Category: Allergy & Immunology Source Type: research

Rituximab, MS, and pregnancy
Conclusion We observed no increase in adverse pregnancy outcomes compared with expected national incidence rates and remarkably little disease activity in RTX-treated women with MS, particularly when compared with periconceptional natalizumab-treated cohorts. However, larger studies are needed to fully assess the safety of RTX use before pregnancy, especially risks associated with prolonged B-cell depletion and hypogammaglobulinemia. Until these data are available, we recommend restricting RTX use before pregnancy to women who require highly effective MS treatments. Classification of evidence This study provides Class IV ...
Source: Neurology Neuroimmunology and Neuroinflammation - April 30, 2020 Category: Neurology Authors: Smith, J. B., Hellwig, K., Fink, K., Lyell, D. J., Piehl, F., Langer-Gould, A. Tags: Multiple sclerosis Article Source Type: research

Immune Responses and Anti-inflammatory Strategies in a Clinically Relevant Model of Thromboembolic Ischemic Stroke with Reperfusion
AbstractThe poor clinical relevance of experimental models of stroke contributes to the translational failure between preclinical and clinical studies testing anti-inflammatory molecules for ischemic stroke. Here, we (i) describe the time course of inflammatory responses triggered by a thromboembolic model of ischemic stroke and (ii) we examine the efficacy of two clinically tested anti-inflammatory drugs: Minocycline or anti-CD49d antibodies (tested in stroke patients as Natalizumab) administered early (1  h) or late (48 h) after stroke onset. Radiological (lesion volume) and neurological (grip test) outcomes were evalu...
Source: Translational Stroke Research - September 13, 2019 Category: Neurology Source Type: research

Topline Results Negative for MS Drug in Acute Stroke Topline Results Negative for MS Drug in Acute Stroke
After natalizumab showed some initial promise in improving clinical outcomes in acute ischemic stroke in a phase 2a study, a phase 2b trial of the drug finds no clinical benefit.Medscape Medical News
Source: Medscape Medical News Headlines - February 9, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Biogen stops testing Tysabri to treat stroke after study fails
(Reuters) - Biogen Inc said on Wednesday it would stop developing its multiple sclerosis drug Tysabri to treat patients with acute ischemic stroke after it failed a mid-stage study.
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biogen stops developing Tysabri to treat stroke after failed study
(Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study.
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Can natalizumab be beneficial in acute ischaemic stroke?
Publication date: March 2017 Source:The Lancet Neurology, Volume 16, Issue 3 Author(s): Turgut Tatlisumak
Source: The Lancet Neurology - February 15, 2017 Category: Neurology Source Type: research

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Publication date: March 2017 Source:The Lancet Neurology, Volume 16, Issue 3 Author(s): Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta, Mitchell S V Elkind Background In animal models of acute ischaemic stroke, blocking of the leukocyte-endothelium adhesion by antagonism of α4 integrin reduces infarct volumes and improves outcomes. We assessed the effect of one dose of natalizumab, an antibody against the leukocyte adhesion molecule α4 integrin, in patients with acute ischaemic st...
Source: The Lancet Neurology - February 15, 2017 Category: Neurology Source Type: research

Comment Can natalizumab be beneficial in acute ischaemic stroke?
Experimental and clinical evidence suggests an early activation of the immune system after brain ischaemia, with rapid invasion of ischaemic regions by leucocytes and an increase in complement concentrations in blood.1 –3 Natalizumab is a humanised monoclonal antibody against α4 integrin, a glycoprotein that is expressed on the surface of lymphocytes and monocytes and facilitates their adhesion to the endothelial vessel wall; natalizumab was approved for use as monotherapy in relapsing-remitting multiple sclero sis over a decade ago.
Source: Lancet Neurology - February 15, 2017 Category: Neurology Authors: Turgut Tatlisumak Tags: Comment Source Type: research

Articles Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Natalizumab administered up to 9 h after stroke onset did not reduce infarct growth. Treatment-associated benefits on functional outcomes might warrant further investigation.
Source: Lancet Neurology - February 15, 2017 Category: Neurology Authors: Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta, Mitchell S V Elkind Tags: Articles Source Type: research

Natalizumab: a new therapy for acute ischemic stroke?
This article reviews the main experimental studies on the blockage of CD49d and identifies the potential underlying causes for their inconclusive results. Despite these divergences and the difficulties in translation of experimental studies, a phase II clinical trial has recently been conducted to evaluate the efficacy of Natalizumab in stroke patients (ACTION trial). Preliminary results of the trial are also discussed here, together with a general overview of the emerged importance of the neuroprotective strategies based on the mitigation of post-stroke neuroinflammation. Expert commentary: Despite Natalizumab showing pos...
Source: Expert Review of Neurotherapeutics - August 2, 2016 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Clinical Trials of Immunomodulation in Ischemic Stroke
Abstract Inflammatory mechanisms are currently considered as a prime target for stroke therapy. There is evidence from animal studies that immune signals and mediators can have both detrimental and beneficial effects in particular stages of the disease process. Moreover, several of these mechanisms are turned on with sufficient delay after ischemia onset to make them amenable to therapeutic intervention. Several clinical proof-of concept trials have investigated the efficacy of different immunomodulatory approaches in patients with stroke. Trials targeting the innate immune system have focused on reduction of micr...
Source: Neurotherapeutics - July 12, 2016 Category: Neurology Source Type: research

Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation
Publication date: Available online 11 May 2016 Source:The Lancet Neurology Author(s): Ángel Chamorro, Ulrich Dirnagl, Xabier Urra, Anna M Planas Treatments for acute ischaemic stroke continue to evolve after the superior value of endovascular thrombectomy was confirmed over systemic thrombolysis. Unfortunately, numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischaemic stroke, making the search for new treatments imperative. Increased awareness of the relevance of rigorous preclinical testing, and appropriate selection of study participants, might overcome the barriers to progress...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research

What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news